Banco Bilbao Vizcaya Argentaria S.A. Has $20.72 Million Position in Intuitive Surgical, Inc. $ISRG

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 14.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 41,800 shares of the medical equipment provider's stock after purchasing an additional 5,245 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Intuitive Surgical were worth $20,718,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Castleark Management LLC lifted its position in shares of Intuitive Surgical by 3.4% during the fourth quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock worth $47,221,000 after purchasing an additional 2,990 shares in the last quarter. Arlington Trust Co LLC boosted its holdings in Intuitive Surgical by 34.5% in the first quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock valued at $369,000 after acquiring an additional 191 shares during the last quarter. Aveo Capital Partners LLC increased its position in Intuitive Surgical by 37.4% in the first quarter. Aveo Capital Partners LLC now owns 727 shares of the medical equipment provider's stock worth $390,000 after purchasing an additional 198 shares during the period. Aaron Wealth Advisors LLC raised its holdings in Intuitive Surgical by 3.2% during the 1st quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider's stock worth $1,243,000 after purchasing an additional 78 shares during the last quarter. Finally, Longbow Finance SA lifted its position in Intuitive Surgical by 132.0% during the 1st quarter. Longbow Finance SA now owns 19,699 shares of the medical equipment provider's stock valued at $9,756,000 after purchasing an additional 11,209 shares during the period. 83.64% of the stock is owned by institutional investors.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the transaction, the executive vice president directly owned 353 shares in the company, valued at approximately $173,845.44. The trade was a 92.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,839 shares of company stock valued at $7,896,972 over the last 90 days. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $10.57 during midday trading on Thursday, reaching $469.88. 2,465,052 shares of the stock were exchanged, compared to its average volume of 1,980,181. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The company has a market capitalization of $168.44 billion, a price-to-earnings ratio of 65.53, a P/E/G ratio of 5.04 and a beta of 1.59. The business has a 50-day simple moving average of $505.14 and a two-hundred day simple moving average of $522.78.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The firm's revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.78 EPS. Equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Citigroup reiterated a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Robert W. Baird lowered their target price on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Wall Street Zen raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. UBS Group raised their price target on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $595.00 price objective (up previously from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Thirteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.